Wechselwirkungen · Rubraca
Rubraca 200 mg film-coated tablets Rubraca 250 mg film-coated tablets Rubraca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-137462 · Präparat HOS-098043
CYP2C9 substrates Rucaparib increased S-warfarin Cmax by 1.05 fold (90% CI: 0.99 to 1.12) and AUC0-96 h by 1.49 fold (90% CI: 1.40 to 1.58), respectively. When co-administering medicinal products that are CYP2C9 substrates with a narrow therapeutic index (e.g., warfarin, phenytoin), dose adjustments may be considered, if clinically indicated. Caution should be exercised and additional International Normalised Ratio (INR) monitoring with co-administration of warfarin and therapeutic drug level monitoring of phenytoin should be considered, if used concomitantly with rucaparib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-27T16:36:00Z · SHA-256 230a9c1df880b14750043bea049c21874a6e3d04bb3b18b3f15c92b0c4aa3f16 · Passage 2c2096f9d2d770855fc24820262fa3dfe884d43f599bd9a993814d1f0e96bbbf · Zeichen 1787–2368 im Abschnitt